Marriott International Inc. - Class A (MAR)
Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) subsidiary Marea Therapeutics has dosed the first patient in a Phase 2 clinical trial of MAR002, a first-in-class antibody therapy for acromegaly, the company said on Monday. Marea, which is developing medicines for cardioendocrine diseases, is advancing MAR002 as a potential new option for the rare endocrine disorder.
Why Is Marriott (MAR) Down 3.1% Since Last Earnings Report?
Marriott (MAR) reported earnings 30 days ago. What's next for the stock?
Here's Why Marriott International (MAR) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Marriott: The Loyalty Engine Is Outgrowing The Hotel Cycle
Marriott International is rated Buy, with a fair value estimate of $400, reflecting premium quality at a relative discount to Hilton. MAR's earnings growth is driven by robust fee revenue, Bonvoy membership expansion, co-branded credit card income, and aggressive share repurchases, despite modest RevPAR gains. Net room growth, conversions, and a large pipeline support sustained high-single-digit fee and EBITDA growth, with 2026–2027 EPS projected to rise 11–14% annually.
Can Marriott's Raised 2026 Outlook Overcome Middle East Weakness?
MAR raises its 2026 outlook on stronger U.S. demand and fee growth, but Middle East weakness still clouds RevPAR, openings and execution.
Is Marriott Stock Worth Buying as Growth Meets a Premium Valuation?
MAR's fee growth and record pipeline bolster its outlook, but a rich valuation, rising debt and regional volatility argue for patience.
Marriott's Earnings Drop May Be Missing the Bigger Fee Growth Story
Marriott International TodayMARMarriott International$341.35 -5.48 (-1.58%) As of 12:15 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$255.27▼$410.98Dividend Yield0.86%P/E Ratio35.85Price Target$387.24Add to WatchlistInvestors checked out on Marriott International NYSE: MAR, sending the stock down nearly 7%, after the company delivered its Q2 2026 earnings report.
Marriott Adds AI-Powered Conversational Search Tool to Drive Direct Bookings
Global hospitality company Marriott International accelerated the deployment of artificial intelligence (AI) solutions for customers of its properties and its travel platform during the second quarter. “In June, we began our phased rollout of Ask Bonvoy, our AI-powered conversational search experience on Marriott.
MAR Q2 Earnings Beat Estimates, Revenues Miss, RevPAR Rises
MAR beats earnings estimates as fee growth, RevPAR gains and room expansion supported profit despite a revenue miss.
Compared to Estimates, Marriott (MAR) Q2 Earnings: A Look at Key Metrics
The headline numbers for Marriott (MAR) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Marriott International Q2 Earnings Call Highlights
Marriott International NASDAQ: MAR reported second-quarter results that exceeded its prior expectations, driven by global revenue per available room growth, expanding fee revenue and continued portfolio growth. The company raised its full-year 2026 outlook for global RevPAR, gross fee revenue, adjusted EBITDA and adjusted diluted earnings per share.
Marriott International (MAR) Q2 Earnings Top Estimates
Marriott International (MAR) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.06 per share. This compares to earnings of $2.65 per share a year ago.
